Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...
Ingelheim, Germany Saturday, February 15, 2025, 12:00 Hrs [IST] ...
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.
A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...
Researchers from Cologne, Bochum, Padova and Angers have discovered a novel connection between mitochondrial function, ...
Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...
A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback